North East and North Cumbria
ICS Formulary
ICS Formulary
1 Gastro-intestinal system
01-02 Other antispasmodics
| Mebeverine |
|
Formulary
|
|
|
| Mebeverine |
|
Non Formulary
|
200mg modified-release capsules
For preferred preparations, see main formulary entry above |
|
Links
Guidelines for the Management of Adults with Asymptomatic Liver Blood Test Abnormalities- MHRA Drug Safety Update (Feb 2017): Hyoscine butylbromide (Buscopan) injection: risk of serious adverse effects in patients with underlying cardiac disease
- MHRA DSU (Aug 2013): Metoclopramide: risk of neurological adverse effects
- MHRA DSU (Dec 2019): Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents
- MHRA DSU (July 2026): Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension
- MHRA DSU (May 2014): Domperidone: risk of cardiac side effects
- NICE CG49: Faecal incontinence
- NICE CG99: Constipation in children and young people
- NICE NG71: Parkinson’s disease in adults
- NTAG: Transanal irrigation (TAI) systems (Peristeen Plus®, Aquaflush®, and QuFora®) for neurogenic bowel dysfunction, chronic constipation and chronic faecal incontinence